GTBP
Price:
$0.514
Market Cap:
$5.46M
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced...[Read more]
Industry
Biotechnology
IPO Date
2018-03-27
Stock Exchange
NASDAQ
Ticker
GTBP
According to GT Biopharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.08. This represents a change of -88.45% compared to the average of -0.69 of the last 4 quarters.
The mean historical PE Ratio of GT Biopharma, Inc. over the last ten years is -14.29. The current -0.08 PE Ratio has changed -44.02% with respect to the historical average. Over the past ten years (40 quarters), GTBP's PE Ratio was at its highest in in the June 2016 quarter at 1.52. The PE Ratio was at its lowest in in the December 2017 quarter at -278.13.
Average
-14.29
Median
-3.70
Minimum
-44.42
Maximum
0.24
Discovering the peaks and valleys of GT Biopharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 826.80%
Maximum Annual PE Ratio = 0.24
Minimum Annual Increase = -6614.42%
Minimum Annual PE Ratio = -44.42
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -0.13 | -71.41% |
| 2024 | -0.44 | -67.60% |
| 2023 | -1.36 | -96.63% |
| 2022 | -40.26 | -9.37% |
| 2021 | -44.42 | 32.49% |
| 2020 | -33.53 | 826.80% |
| 2019 | -3.62 | -4.30% |
| 2018 | -3.78 | -75.81% |
| 2017 | -15.63 | -6614.42% |
| 2016 | 0.24 | -384.30% |
The current PE Ratio of GT Biopharma, Inc. (GTBP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.64
5-year avg
-17.32
10-year avg
-14.29
GT Biopharma, Inc.’s PE Ratio is less than Artelo Biosciences, Inc. (-0.07), greater than Protagenic Therapeutics, Inc. (-0.12), less than Carisma Therapeutics, Inc. (0.10), greater than Salarius Pharmaceuticals, Inc. (-0.19), less than Windtree Therapeutics, Inc. (-0.00), less than Psyence Biomedical Ltd. (1.77), less than Silexion Therapeutics Ltd. (0.06), less than Lipella Pharmaceuticals Inc. (-0.07), greater than Dermata Therapeutics, Inc. (-0.22), less than Revelation Biosciences, Inc. (-0.07),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.07 | $2.94M | |
| -0.12 | $742.18K | |
| 0.10 | $795.06K | |
| -0.19 | $4.92M | |
| -0.00 | $674.18K | |
| 1.77 | $59.91K | |
| 0.06 | $1.14M | |
| -0.07 | $369.67K | |
| -0.22 | $797.42K | |
| -0.07 | $3.83M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GT Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like GT Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is GT Biopharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for GT Biopharma, Inc. (GTBP)?
What is the highest PE Ratio for GT Biopharma, Inc. (GTBP)?
What is the 3-year average PE Ratio for GT Biopharma, Inc. (GTBP)?
What is the 5-year average PE Ratio for GT Biopharma, Inc. (GTBP)?
How does the current PE Ratio for GT Biopharma, Inc. (GTBP) compare to its historical average?